

Supplement Table 1. Estimated adjusted Hazard Ratios (95%CI) for Invasive Cervical Cancer (ICC) according to baseline categories of Serum Gamma-glutamyltransferase and Tumour Staging, VHM&PP 1985-2003*

ICC Tumour Staging	Serum Gamma-glutamyltransferase (GGT)						
	Normal Low (<17.99 U/L)	Normal High (18.00-35.99 U/L)	Elevated (36.00-71.99 U/L)	Highly Elevated (>72.00 U/L)	p for trend across GGT categories†	HR for GGT log- unit increase§	p for GGT log-unit increase§
Early Stage Tumors (FIGO Stage I & II) (n=79)	1.00 (Ref)	2.68 (1.59-4.52)	3.06 (1.46-6.43)	3.24 (1.20-8.72)	<0.001	4.04 (1.96-8.33)	<0.001
Late Stage Tumors (FIGO Stage III & IV) (n=17)	1.00 (Ref)	2.60 (0.66-10.3)	4.65 (1.00-21.6)	6.69 (1.31-34.2)	<0.01	4.83 (1.24-17.4)	0.016

*Participants with baseline GGT >600 U/L or with history of malignancies prior to enrolment were excluded. GGT measurements at first visit were used in the analyses. Note that for 21 ICC cases staging of the primary tumour was not assessed.

†p-values for log-linear trend were calculated using baseline GGT categories as an ordinal variable in Cox proportional hazards regression runs adjusted for age, body-mass-index, occupational status, smoking status, year of entry into the cohort, number of gynaecological examinations and baseline cytology (within ±6 month from baseline GGT measurement).

§Estimated from Cox Proportional Hazards regression adjusted for age, body-mass-index, occupational status, smoking status, year of entry into the cohort, number of gynaecological examinations and baseline cytology (within ±6 month from baseline GGT measurement).